Gilead Sciences stock (US3755581036): Q1 earnings meet expectations, analyst target adjusted

Gilead Sciences reported Q1 revenues of $7.0 billion and EPS of $1.61, aligning with analyst forecasts. Rothschild & Co Redburn lowered its price target to $167 from $170 on May 11, 2026.

Gilead Sciences released its first-quarter 2026 earnings, posting revenues of $7.0 billion and statutory earnings per share of $1.61, matching analyst expectations, Moomoo as of May 2026. The results showed quarterly revenue up 4.4% year-over-year, with a net margin of 30.99% and return on equity of 48.19%, MarketBeat as of May 11, 2026. Separately, Rothschild & Co Redburn cut its price target on the NASDAQ:GILD stock to $167 from $170, suggesting 24.5% upside potential from recent levels.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: United States
• Core markets: US, Europe, Global
• Key revenue drivers: HIV treatments, Oncology, Liver disease
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences focuses on developing and commercializing therapies for life-threatening diseases, with a strong emphasis on virology, oncology, and inflammation. The company markets leading HIV treatments like Biktarvy, which remains a cornerstone of its portfolio. Its business model relies on innovation in antivirals and targeted cancer therapies, supported by a global commercial presence. For US investors, Gilead's Nasdaq listing and heavy US revenue exposure make it a key player in the biotech sector.

Main revenue and product drivers for Gilead Sciences

HIV franchises drive the majority of revenues, with products generating steady growth. Oncology has gained traction through acquisitions like the recent Arcelix deal, bolstering cell therapy capabilities, as noted in recent coverage. Liver disease treatments also contribute significantly. Quarterly revenue rose 4.4% in Q1 2026 versus the prior year, per MarketBeat as of May 11, 2026. Gilead maintains an annual dividend of $3.28 per share, yielding 2.46% at recent prices, paid quarterly with the next ex-date in June 2026, Stock Analysis as of Mar 27, 2026.

Industry trends and competitive position

The biotech sector faces patent cliffs and pricing pressures, but Gilead's diversified portfolio positions it well against peers like Pfizer and Merck. Its oncology push counters HIV maturity risks. Consensus analyst views remain positive, with 24 Buy ratings and an average target of $157.04, amid Q1 execution.

Why Gilead Sciences matters for US investors

As a Nasdaq-listed biotech giant, Gilead offers US investors exposure to high-margin pharmaceuticals amid healthcare spending growth. Its HIV dominance and oncology expansion align with US market demands, with over half of revenues from domestic sales.

Conclusion

Gilead Sciences delivered Q1 results in line with expectations, supporting its stable execution amid analyst adjustments. Dividend consistency and pipeline progress provide visibility. US investors track its role in biotech innovation and market dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.